{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:42:36Z","timestamp":1792676556294,"version":"4.5.0"},"reference-count":127,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Central nervous system lymphoma (CNSL) is a rare form of extranodal non-Hodgkin lymphoma. Central nervous system lymphoma can be primary (isolated to the central nervous space) or secondary in the setting of systemic disease. Treatment of CNSL has improved since the introduction of high-dose methotrexate and aggressive consolidation regimens. However, results after treatment are durable in only half of patients, and long-term survivors may experience late neurotoxicity, impacting quality of life. Given the rarity of this disease, few randomized prospective trials exist. This leaves many questions unanswered regarding optimal first-line and salvage treatments. Recent advances in the knowledge of pathophysiology of CNSL will hopefully help the development of future treatments. This review gives an overview of the epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment of immunocompetent patients with CNSL.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000449","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T21:02:18Z","timestamp":1591909338000},"page":"241-252","source":"Crossref","is-referenced-by-count":26,"title":["Central Nervous System Lymphoma"],"prefix":"10.1097","volume":"26","author":[{"given":"Carlos Eduardo","family":"Correia","sequence":"first","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren R.","family":"Schaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Grommes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","year":"2011","journal-title":"Br J Cancer"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016","volume":"21","year":"2019","journal-title":"Neuro Oncol"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind\u2014changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume":"20","year":"2018","journal-title":"Neuro Oncol"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23551","article-title":"The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma","volume":"88","year":"2013","journal-title":"Am J Hematol"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516\u2014the Southwest Oncology Group","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib6-20230924","first-page":"699","article-title":"Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A review of 36 cases","volume":"60","year":"1986","journal-title":"Q J Med"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","article-title":"Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model","volume":"13","year":"2002","journal-title":"Ann Oncol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","article-title":"Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma","volume":"91","year":"1998","journal-title":"Blood"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2014a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"18","year":"2007","journal-title":"Ann Oncol"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11912-015-0450-4","article-title":"Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?","volume":"17","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1349-7006.2010.01555.x","article-title":"Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients","volume":"101","year":"2010","journal-title":"Cancer Sci"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","year":"2014","journal-title":"Br J Haematol"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3171\/jns.2000.92.2.0261","article-title":"Primary intracerebral malignant lymphoma: report of 248 cases","volume":"92","year":"2000","journal-title":"J Neurosurg"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11060-010-0303-9","article-title":"Ocular involvement in patients with primary CNS lymphoma","volume":"102","year":"2011","journal-title":"J Neurooncol"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1182\/blood-2009-12-258210","article-title":"Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.eye.6700378","article-title":"Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes","volume":"17","year":"2003","journal-title":"Eye (Lond)"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s003300101037","article-title":"Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients","volume":"12","year":"2002","journal-title":"Eur Radiol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1126\/science.3563523","article-title":"Glucocorticoid receptor\u2013like antigen in lymphoma cell membranes: correlation to cell lysis","volume":"236","year":"1987","journal-title":"Science"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1006254518848","article-title":"Glucocorticoid treatment of primary CNS lymphoma","volume":"43","year":"1999","journal-title":"J Neurooncol"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejso.2004.10.002","article-title":"Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases","volume":"31","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008201717089","article-title":"Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature","volume":"8","year":"1997","journal-title":"Ann Oncol"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1093\/annonc\/mdr627","article-title":"Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial","volume":"23","year":"2012","journal-title":"Ann Oncol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/neuonc\/nop053","article-title":"Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort","volume":"12","year":"2010","journal-title":"Neuro Oncol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","year":"2016","journal-title":"Acta Neuropathol"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ajcp\/110.5.607","article-title":"Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'\u00e9tude des Leuc\u00e9nies et Autres Maladies du Sang (GOELAMS)","volume":"110","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","year":"2000","journal-title":"Nature"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","year":"2004","journal-title":"Blood"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","article-title":"A uniform activated B-cell\u2013like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases","volume":"107","year":"2006","journal-title":"Blood"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/blood-2007-10-119099","article-title":"Pathway analysis of primary central nervous system lymphoma","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","year":"2015","journal-title":"Semin Hematol"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/leu.2014.264","article-title":"The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing","volume":"29","year":"2015","journal-title":"Leukemia"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","year":"2015","journal-title":"Clin Cancer Res"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","article-title":"Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma","volume":"122","year":"2011","journal-title":"Acta Neuropathol"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00401-012-1064-7","article-title":"Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma","volume":"124","year":"2012","journal-title":"Acta Neuropathol"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","year":"2012","journal-title":"Clin Cancer Res"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.18632\/oncotarget.2080","article-title":"Mutational analysis of primary central nervous system lymphoma","volume":"5","year":"2014","journal-title":"Oncotarget"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/bcj.2013.28","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"3","year":"2013","journal-title":"Blood Cancer J"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.2399","article-title":"Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways","volume":"216","year":"2008","journal-title":"J Pathol"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e318266fcb2","article-title":"Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial","volume":"79","year":"2012","journal-title":"Neurology"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000226454","article-title":"Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients","volume":"44","year":"1987","journal-title":"Oncology"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood-2007-07-101402","article-title":"Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12987-017-0064-3","article-title":"Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease","volume":"14","year":"2017","journal-title":"Fluids Barriers CNS"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","article-title":"Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors","volume":"80","year":"2006","journal-title":"J Neurooncol"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/sj.bjc.6690083","article-title":"Second-line treatment for primary central nervous system lymphoma","volume":"79","year":"1999","journal-title":"Br J Cancer"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/neuonc\/nor014","article-title":"Late relapse in primary central nervous system lymphoma: clonal persistence","volume":"13","year":"2011","journal-title":"Neuro Oncol"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","article-title":"Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315","volume":"23","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","article-title":"Combined modality therapy for primary CNS lymphoma","volume":"10","year":"1992","journal-title":"J Clin Oncol"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3171\/jns.1994.81.2.0188","article-title":"Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome","volume":"81","year":"1994","journal-title":"J Neurosurg"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1996.14.2.556","article-title":"Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06","volume":"14","year":"1996","journal-title":"J Clin Oncol"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0360-3016(98)00450-7","article-title":"Primary central nervous system non-Hodgkin's lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52","volume":"43","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2000.18.3.519","article-title":"Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma","volume":"18","year":"2000","journal-title":"J Clin Oncol"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","article-title":"Treatment for primary CNS lymphoma: the next step","volume":"18","year":"2000","journal-title":"J Clin Oncol"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000055310","article-title":"Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients","volume":"60","year":"2001","journal-title":"Oncology"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10","volume":"20","year":"2002","journal-title":"J Clin Oncol"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","year":"2009","journal-title":"Lancet"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","year":"2010","journal-title":"Lancet Oncol"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.10102","article-title":"German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma","volume":"51","year":"2002","journal-title":"Ann Neurol"},{"key":"bib67-20230924","first-page":"711","article-title":"High-dose methotrexate for intraocular lymphoma","volume":"9","year":"2003","journal-title":"Clin Cancer Res"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","article-title":"Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","year":"2016","journal-title":"Lancet Haematol"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immunochemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","year":"2017","journal-title":"Leukemia"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","article-title":"Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","article-title":"High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group","volume":"38","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","article-title":"High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","article-title":"High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial","volume":"3","year":"2016","journal-title":"Lancet Haematol"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncr.11035","article-title":"Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation","volume":"97","year":"2003","journal-title":"Cancer"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1097-0142(19870701)60:1<5::AID-CNCR2820600103>3.0.CO;2-D","article-title":"A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g\/m2 in children with acute lymphoblastic leukemia","volume":"60","year":"1987","journal-title":"Cancer"},{"key":"bib80-20230924","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0360-3016(01)01639-X","article-title":"Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate","volume":"51","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","article-title":"Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib82-20230924","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.3109\/10428194.2016.1167203","article-title":"Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech Lymphoma Study Group Registry","volume":"57","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.24204","article-title":"Rituximab with high-dose methotrexate in primary central nervous system lymphoma","volume":"90","year":"2015","journal-title":"Am J Hematol"},{"key":"bib84-20230924","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1212\/WNL.0000000000000593","article-title":"High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma","volume":"83","year":"2014","journal-title":"Neurology"},{"key":"bib85-20230924","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/neuonc\/not032","article-title":"Rituximab is associated with improved survival for aggressive B cell CNS lymphoma","volume":"15","year":"2013","journal-title":"Neuro Oncol"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1023\/A:1008371602708","article-title":"Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?","volume":"11","year":"2000","journal-title":"Ann Oncol"},{"key":"bib87-20230924","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/cncr.23077","article-title":"Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma","volume":"110","year":"2007","journal-title":"Cancer"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/phar.1360","article-title":"Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","year":"2014","journal-title":"Pharmacotherapy"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s12185-011-0848-1","article-title":"High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma","volume":"93","year":"2011","journal-title":"Int J Hematol"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","article-title":"A multicenter study of treatment of primary CNS lymphoma","volume":"58","year":"2002","journal-title":"Neurology"},{"key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11060-011-0649-7","article-title":"Prophylactic intrathecal chemotherapy in primary CNS lymphoma","volume":"106","year":"2012","journal-title":"J Neurooncol"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1016077907952","article-title":"Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?","volume":"58","year":"2002","journal-title":"J Neurooncol"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-008-9712-4","article-title":"Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study","volume":"91","year":"2009","journal-title":"J Neurooncol"},{"key":"bib94-20230924","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/annonc\/mdf080","article-title":"Relevance of intraocular involvement in the management of primary central nervous system lymphomas","volume":"13","year":"2002","journal-title":"Ann Oncol"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1212\/01.wnl.0000327672.04729.8c","article-title":"Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group report","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/annonc\/mdl458","article-title":"Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan\/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study","volume":"18","year":"2007","journal-title":"Ann Oncol"},{"key":"bib98-20230924","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1212\/WNL.54.8.1707","article-title":"PCV salvage chemotherapy for recurrent primary CNS lymphoma","volume":"54","year":"2000","journal-title":"Neurology"},{"key":"bib99-20230924","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1034\/j.1600-0609.2003.00045.x","article-title":"Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma","volume":"70","year":"2003","journal-title":"Euro J Haematol"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cncr.20339","article-title":"Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas","volume":"101","year":"2004","journal-title":"Cancer"},{"key":"bib101-20230924","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1212\/01.WNL.0000137050.43114.42","article-title":"Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide","volume":"63","year":"2004","journal-title":"Neurology"},{"key":"bib102-20230924","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","article-title":"Treatment of relapsed central nervous system lymphoma with high-dose methotrexate","volume":"10","year":"2004","journal-title":"Clin Cancer Res"},{"key":"bib103-20230924","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.01.161","article-title":"Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib104-20230924","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","article-title":"Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma","volume":"69","year":"2007","journal-title":"Neurology"},{"key":"bib105-20230924","first-page":"155","article-title":"Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status","volume":"106","year":"2012","journal-title":"Neurology"},{"key":"bib106-20230924","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jocn.2012.04.001","article-title":"A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide","volume":"19","year":"2012","journal-title":"J Clin Neurosci"},{"key":"bib107-20230924","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11060-013-1196-1","article-title":"Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma","volume":"115","year":"2013","journal-title":"J Neurooncol"},{"key":"bib108-20230924","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11060-014-1370-0","article-title":"Methotrexate re-challenge for recurrent primary central nervous system lymphoma","volume":"117","year":"2014","journal-title":"J Neurooncol"},{"key":"bib109-20230924","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-014-1411-8","article-title":"Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series","volume":"118","year":"2014","journal-title":"J Neurooncol"},{"key":"bib110-20230924","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","year":"2015","journal-title":"Neurology"},{"key":"bib111-20230924","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdl070","article-title":"Prospective trial on topotecan salvage therapy in primary CNS lymphoma","volume":"17","year":"2006","journal-title":"Ann Oncol"},{"key":"bib112-20230924","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","article-title":"Temozolomide as salvage treatment in primary brain lymphomas","volume":"96","year":"2007","journal-title":"Br J Cancer"},{"key":"bib113-20230924","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","article-title":"Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle Osseuse-Th\u00e9rapie Cellulaire","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib114-20230924","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","year":"2011","journal-title":"Neurology"},{"key":"bib115-20230924","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/cncr.26709","article-title":"Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma","volume":"118","year":"2012","journal-title":"Cancer"},{"key":"bib116-20230924","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/10428194.2012.698736","article-title":"Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma","volume":"54","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"bib117-20230924","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","article-title":"Phase II trial of temsirolimus for relapsed\/refractory primary CNS lymphoma","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib118-20230924","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase II study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)\u2020","volume":"30","year":"2019","journal-title":"Ann Oncol"},{"key":"bib119-20230924","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib120-20230924","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC Network","volume":"18","year":"2016","journal-title":"Neuro Oncol"},{"key":"bib121-20230924","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V128.22.784.784","article-title":"Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the LYSA and the French LOC Network","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib122-20230924","first-page":"vi3","article-title":"Phase II study of single agent buparlisib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)","volume":"18","year":"2016","journal-title":"Neurooncology"},{"key":"bib123-20230924","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V128.22.785.785","article-title":"Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a \u201cproof of concept\u201d phase II Study of the French LOC Network","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib124-20230924","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.15009","article-title":"Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model","volume":"183","year":"2018","journal-title":"Br J Haematol"},{"key":"bib125-20230924","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib126-20230924","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","year":"2018","journal-title":"Blood Adv"},{"key":"bib127-20230924","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-007-9464-6","article-title":"Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma","volume":"86","year":"2008","journal-title":"J Neurooncol"},{"key":"bib128-20230924","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","year":"2019","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:27:15Z","timestamp":1695533235000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000449"}},"subtitle":["Approach to Diagnosis and Treatment"],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000449","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}